Access and Benefit Sharing Workshop
Understanding the Nagoya Protocol and dealing with its national implementation
- Nagoya Protocol: understanding the general principles and dealing with the national implementation on a global basis
- What to do from an ABS compliance point of view: acquiring genetic resources for R&D programmes and commercializing products on the market
- Implementing ABS policies in companies to comply with Nagoya
- Digital sequence information: potential regulation and significant challenges arising for research organizations
- Detailed case studies for access, track & trace and compliance declaration
Aims and objectivesCompanies relying on genetic material for their products and institutions researching genetic material need to deal with the Nagoya Protocol, which aims at sharing the benefits arising from the utilization of genetic resources in a fair and equitable way.In practice, challenges arise from managing access, managing track and trace, managing reporting and dealing with audits and non-compliance allegations. Attendees will better understand the access and benefit sharing (ABS) legal regime.
This practical course shall enable attendees to deal with the ABS challenges and to find pragmatic solutions for their problems.
Then this is the right course for you. Knowledge on access and benefit sharing is not a prerequisite.
- Access requirements in the Nagoya Protocol: what is defined - what not?
- Commercializing of new products on the market: what is defined - what not?
- Brazil/China/India/USA: status of CBD and Nagoya protocol membership, status of legislation
- EU: focus on the commercialization of products
- Selecting the country of acquiring R&D material
- Negotiating contracts: prior informed consent/mutually agreed terms
- Confidentiality of data
- Export of acquired R&D material
- Internal administration systems; track & trace
- External audits and internal audit system
- User compliance declaration
- Benefit sharing
- Research Collaborations
- Acquiring products for further R&D activities
- Access and commercialization in an international context
- What is Digital Sequence Information and how should a system work?
- Case study: Brazil
Michael Kock is founder of his own IP and strategy consulting firm. From 2007 to October 2017 Michael was Head Intellectual Property for Syngenta Crop Protection AG based in Basel, Switzerland. He studied chemistry, biochemistry and molecular biology in Hamburg, Germany, and Nanjing, China, and graduated with a Diploma in chemistry and has a Ph.D. in molecular biology. Michael Kock is also a qualified Swiss and European Patent Attorney.
Michael Muschick is the former Global Head Germplasm Legal & IP with Syngenta International AG and currently in a sabbatical. In this position among other things, he was responsible for all aspects related to biodiversity laws within Syngenta. He is currently a member of the ICC ABS task force, ISF Sustainability Committee and ESA Working Group Biodiversity. Before his current position with Syngenta, he served as Secretary General of the International Seed Testing Association (ISTA) for 14 years, being responsible for the worldwide harmonization of seed quality determination.
NL 1054 Amsterdam
Phone: +31 20 6075555
Fax: +31 20 60075511
If you also register to the IP Protection for Plant Innovation Conference in Amsterdam on 28 and 29 November 2019, then you will benefit from a special attendance fee of € 520.
The seminar aims to give a practical, in-depth understanding of the European Patent System.
20. - 21.11.2019 in Amsterdam/Leiden
IP Strategy! - the interactive course which helps you setting up convincing IP strategy plans.
26. - 28.11.2019 in München
Learn in this hands-on course how to improve your patent portfolio management skills. Get more information and register here!
21. - 22.11.2019 in Amsterdam
This practical course centers around an interactive case study that provides participants with a hands-on analysis of US patent law in comparison to European Law. Special attention will be paid to US practice in the post-AIA world.
14.11.2019 in Amsterdam/Leiden
First-hand update for patent practitioners & EQE candidates: Each year the boards of appeal of the European Patent Office hand down more than 2000 decisions. These decisions set the standard for interpreting and applying the European Patent Convention (EPC).
15.11.2019 in Amsterdam